Filing Flows › X4 Pharmaceuticals (XFOR) › Q1 2026
X4 Pharmaceuticals (XFOR) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
X4 Pharmaceuticals (XFOR) reported revenue of $2.5M for the first quarter 2026 (Q1 2026), +178% from a year earlier and -92% from the quarter before. Operating margin was -812.2%, net loss $20.2M (809.6% of revenue).
X4 Pharmaceuticals, Q1 2026: revenue $2.5M (+178% year over year), operating margin -812.2%, net loss $20.2M, operating cash flow −$19.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.5M | -92% | +178% |
| Operating profit | −$20.3M | — | — |
| Net earnings | −$20.2M | — | -7278% |
| Operating cash flow | −$19.6M | — | — |
What changed
Revenue was $2.5M in Q1 2026, up 178% year over year and down 92% from the previous quarter. Product revenue, net was the largest line at 99% of revenue. Product revenue, net added $1.5M year over year (up 162%), 95% of the total change. License and other revenue declined 99%.
Operating costs exceeded revenue by $20.3M, an operating margin of -812.2%. Total costs grew 120% against revenue growth of 178%. The quarter ended with a net loss of $20.2M, narrower than the previous quarter's $23.9M loss.
Operating cash flow was −$19.6M. Non-cash charges added back $223K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $2.0M.
Questions
What was X4 Pharmaceuticals' revenue in the first quarter 2026?
X4 Pharmaceuticals (XFOR) reported revenue of $2.5M for the first quarter 2026 (Q1 2026), +178% from a year earlier and -92% from the quarter before.
Was X4 Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $20.3M (-812.2% of revenue) and net loss $20.2M.
Source: X4 Pharmaceuticals 10-Q on SEC EDGAR.